INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2025

Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2025								December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,098)	$	—	$	2,622	$	10,720	$	(7,749)	$	—	$	2,971
Intangible asset – axicabtagene ciloleucel	7,110		(2,924)		—		4,186		7,110		(2,721)		—		4,389
Intangible asset – Trodelvy	11,730		(3,623)		—		8,107		11,730		(3,083)		—		8,647
Intangible asset – Hepcludex	845		(372)		—		473		845		(329)		—		516
Other	1,479		(1,001)		1		479		1,474		(940)		1		535
Total finite-lived assets	31,884		(16,019)		1		15,866		31,879		(14,822)		1		17,058
Indefinite-lived assets – IPR&D(1)	2,700		—		—		2,700		2,890		—		—		2,890
Total intangible assets	$	34,584	$	(16,019)	$	1	$	18,566	$	34,769	$	(14,822)	$	1	$	19,948

_______________________________

(1) The Indefinite-lived assets – IPR&D balance as of June 30, 2025 was comprised of $1.75 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $950 million related to bulevirtide. See “2025 Impairment” below for 2025 activity.

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2025								December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(8,098)	$	—	$	2,622	$	10,720	$	(7,749)	$	—	$	2,971
Intangible asset – axicabtagene ciloleucel	7,110		(2,924)		—		4,186		7,110		(2,721)		—		4,389
Intangible asset – Trodelvy	11,730		(3,623)		—		8,107		11,730		(3,083)		—		8,647
Intangible asset – Hepcludex	845		(372)		—		473		845		(329)		—		516
Other	1,479		(1,001)		1		479		1,474		(940)		1		535
Total finite-lived assets	31,884		(16,019)		1		15,866		31,879		(14,822)		1		17,058
Indefinite-lived assets – IPR&D(1)	2,700		—		—		2,700		2,890		—		—		2,890
Total intangible assets	$	34,584	$	(16,019)	$	1	$	18,566	$	34,769	$	(14,822)	$	1	$	19,948

_______________________________